KILL Extending overall survival is less important than quality of life and disease stability for the majority of physicians treating patients with advanced lung cancer following first-line chemotherapy
–(BUSINESS WIRE)– Boehringer Ingelheim requests that their press release NewsItemId: 20150925005203 issued September 25, 2015 entitled “Extending overall survival is less important than quality of life and disease stability for the majority of physicians treating patients with advanced lung cancer following first line-chemotherapy” be killed.
The release was issued prematurely by Boehringer Ingelheim.
A replacement release will not be issued.
View source version on businesswire.com: http://www.businesswire.com/news/home/20150925005203/en/
Contacts
Media Contact
Boehringer Ingelheim
Corporate Communications
Media + PR
Dr Reinhard Malin
Phone: +49 (6132) 77-90815
Fax: +49 (6132) 77 6601
Email: press@boehringer-ingelheim.com